Corrigendum to Peginesatide and erythropoietin stimulate similar erythropoietin receptor-mediated signal transduction and gene induction events [Experimental Hematology., 40, (2012), 575-587], DOI: 10.1016/j.exphem.2012.02.007;Peginesatide and erythropoietin stimulate similar erythropoietin receptor-mediated signal transduction and gene induction events

Experimental Hematology

Volumn 40, Issue 7, 2012, Pages 575-587

  Green, Jennifer M ^a   Leu, Karen ^a   Worth, Angela ^a   Mortensen, Richard B ^a   Martinez, David K ^a   Schatz, Peter J ^a   Wojchowski, Don M ^b   Young, Peter R ^a  

^a AFFYMAX RESEARCH INSTITUTE   (United States)

^b Maine Medical Center Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN RECEPTOR; GLYCOGEN SYNTHASE KINASE 3BETA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEGINESATIDE; PROTEIN KINASE B; RECOMBINANT ERYTHROPOIETIN; STAT3 PROTEIN; STAT5 PROTEIN; SYNAPTOPHYSIN; TYROSINE;

ANALYTIC METHOD; ARTICLE; CELL LYSATE; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; ERYTHROID CELL; ERYTHROPOIESIS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE INDUCTION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LIQUID CHROMATOGRAPHY; MESOSCALE ARRAY; MICROARRAY ANALYSIS; PHOSPHOPROTEOMICS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEOMICS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY;

EID: 84862532659     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2014.04.003     Document Type: Erratum

References (52)

1. Macdougall I.C., Roberts D.E., Neubert P., Dharmasena A.D., Coles G.A., Williams J.D. Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Lancet 1989, 1:425-427.
2. Macdougall I.C. Novel erythropoiesis-stimulating agents: a new era in anemia management. Clin J Am Soc Nephrol 2008, 3:200-207.
3. Wrighton N.C., Farrell F.X., Chang R., et al. Small peptides as potent mimetics of the protein hormone erythropoietin. Science 1996, 273:458-464.
4. Johnson D.L., Farrell F.X., Barbone F.P., et al. Identification of a 13 amino acid peptide mimetic of erythropoietin and description of amino acids critical for the mimetic activity of EMP1. Biochemistry 1998, 37:3699-3710.
5. Livnah O., Stura E.A., Johnson D.L., et al. Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 A. Science 1996, 273:464-471.
6. Fan Q., Leuther K.K., Holmes C.P., et al. Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia. Exp Hematol 2006, 34:1303-1311.
7. Stead R.B., Lambert J., Wessels D., et al. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood 2006, 108:1830-1834.
8. Macdougall I.C. Hematide, a novel peptide-based erythropoiesis-stimulating agent for the treatment of anemia. Curr Opin Invest Drugs 2008, 9:1034-1047.
9. Macdougall I.C., Rossert J., Casadevall N., et al. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med 2009, 361:1848-1855.
10. Wu D., Lim E., Vaillant F., Asselin-Labat M.L., Visvader J.E., Smyth G.K. ROAST: rotation gene set tests for complex microarray experiments. Bioinformatics 2010, 26:2176-2182.
11. Witthuhn B.A., Quelle F.W., Silvennoinen O., et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 1993, 74:227-236.
12. Miura O., Miura Y., Nakamura N., et al. Induction of tyrosine phosphorylation of Vav and expression of Pim-1 correlates with Jak2-mediated growth signaling from the erythropoietin receptor. Blood 1994, 84:4135-4141.
13. Miura O., Nakamura N., Quelle F.W., Witthuhn B.A., Ihle J.N., Aoki N. Erythropoietin induces association of the JAK2 protein tyrosine kinase with the erythropoietin receptor in vivo. Blood 1994, 84:1501-1507.
14. Miura Y., Miura O., Ihle J.N., Aoki N. Activation of the mitogen-activated protein kinase pathway by the erythropoietin receptor. J Biol Chem 1994, 269:29962-29969.
15. Odai H., Sasaki K., Iwamatsu A., et al. The proto-oncogene product c-Cbl becomes tyrosine phosphorylated by stimulation with GM-CSF or Epo and constitutively binds to the SH3 domain of Grb2/Ash in human hematopoietic cells. J Biol Chem 1995, 270:10800-10805.
16. Shigematsu H., Iwasaki H., Otsuka T., Ohno Y., Arima F., Niho Y. Role of the vav proto-oncogene product (Vav) in erythropoietin-mediated cell proliferation and phosphatidylinositol 3-kinase activity. J Biol Chem 1997, 272:14334-14340.
17. Iwatsuki K., Endo T., Misawa H., et al. STAT5 activation correlates with erythropoietin receptor-mediated erythroid differentiation of an erythroleukemia cell line. J Biol Chem 1997, 272:8149-8152.
18. Lecoq-Lafon C., Verdier F., Fichelson S., et al. Erythropoietin induces the tyrosine phosphorylation of GAB1 and its association with SHC, SHP2, SHIP, and phosphatidylinositol 3-kinase. Blood 1999, 93:2578-2585.
19. Boer A.K., Drayer A.L., Vellenga E. Effects of overexpression of the SH2-containing inositol phosphatase SHIP on proliferation and apoptosis of erythroid AS-E2 cells. Leukemia 2001, 15:1750-1757.
20. Bouscary D., Pene F., Claessens Y.E., et al. Critical role for PI 3-kinase in the control of erythropoietin-induced erythroid progenitor proliferation. Blood 2003, 101:3436-3443.
21. Halupa A., Chohan M., Stickle N.H., Beattie B.K., Miller B.A., Barber D.L. Erythropoietin receptor Y479 couples to ERK1/2 activation via recruitment of phospholipase Cgamma. Exp Cell Res 2005, 309:1-11.
22. Miura O., Nakamura N., Ihle J.N., Aoki N. Erythropoietin-dependent association of phosphatidylinositol 3-kinase with tyrosine-phosphorylated erythropoietin receptor. J Biol Chem 1994, 269:614-620.
23. Kirito K., Uchida M., Takatoku M., et al. A novel function of Stat1 and Stat3 proteins in erythropoietin-induced erythroid differentiation of a human leukemia cell line. Blood 1998, 92:462-471.
24. Jacobs-Helber S.M., Ryan J.J., Sawyer S.T. JNK and p38 are activated by erythropoietin (EPO) but are not induced in apoptosis following EPO withdrawal in EPO-dependent HCD57 cells. Blood 2000, 96:933-940.
25. Socolovsky M., Nam H., Fleming M.D., Haase V.H., Brugnara C., Lodish H.F. Ineffective erythropoiesis in Stat5a(-/-)5b(-/-) mice due to decreased survival of early erythroblasts. Blood 2001, 98:3261-3273.
26. Jegalian A.G., Wu H. Differential roles of SOCS family members in EpoR signal transduction. J Interferon Cytokine Res 2002, 22:853-860.
27. Boer A.K., Drayer A.L., Rui H., Vellenga E. Prostaglandin-E2 enhances EPO-mediated STAT5 transcriptional activity by serine phosphorylation of CREB. Blood 2002, 100:467-473.
28. Tsuda H., Huang R.W., Takatsuki K. Role of protein phosphorylation in EPO-mediated early signal transduction: analysis in the EPO-reactive cell line ELM-I-1 transfected with a c-fos-enhancer/promoter-luciferase reporter gene. Eur J Haematol 1994, 52:207-215.
29. Adunyah S.E., Ceesay K.J., Rivero J.A. Regulation of jun expression and activation of AP-1 activity by erythropoietin. Biochem Biophys Res Commun 1996, 221:213-218.
30. Menon M.P., Karur V., Bogacheva O., Bogachev O., Cuetara B., Wojchowski D.M. Signals for stress erythropoiesis are integrated via an erythropoietin receptor-phosphotyrosine-343-Stat5 axis. J Clin Invest 2006, 116:683-694.
31. Longmore G.D. A unique role for Stat5 in recovery from acute anemia. J Clin Invest 2006, 116:626-628.
32. Tanaka M., Miyajima A. Oncostatin M, a multifunctional cytokine. Rev Physiol Biochem Pharmacol 2003, 149:39-52.
33. Tanaka M., Hirabayashi Y., Sekiguchi T., Inoue T., Katsuki M., Miyajima A. Targeted disruption of oncostatin M receptor results in altered hematopoiesis. Blood 2003, 102:3154-3162.
34. Chung B., Verdier F., Matak P., Deschemin J.C., Mayeux P., Vaulont S. Oncostatin M is a potent inducer of hepcidin, the iron regulatory hormone. FASEB J 2010, 24:2093-2103.
35. Tanno T., Bhanu N.V., Oneal P.A., et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007, 13:1096-1101.
36. Nemeth E. Iron regulation and erythropoiesis. Curr Opin Hematol 2008, 15:169-175.
37. Xia Y., Babitt J.L., Sidis Y., Chung R.T., Lin H.Y. Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin. Blood 2008, 111:5195-5204.
38. Forejtnikova H., Vieillevoye M., Zermati Y., et al. Transferrin receptor 2 is a component of the erythropoietin receptor complex and is required for efficient erythropoiesis. Blood 2010, 116:5357-5367.
39. Davey H.W., McLachlan M.J., Wilkins R.J., Hilton D.J., Adams T.E. STAT5b mediates the GH-induced expression of SOCS-2 and SOCS-3 mRNA in the liver. Mol Cell Endocrinol 1999, 158:111-116.
40. Bode J.G., Ludwig S., Freitas C.A., et al. The MKK6/p38 mitogen-activated protein kinase pathway is capable of inducing SOCS3 gene expression and inhibits IL-6-induced transcription. Biol Chem 2001, 382:1447-1453.
41. Zhang L., Badgwell D., Bevers J., et al. IL-6 signaling via the STAT3/SOCS3 pathway: functional analysis of the conserved STAT3 N-domain. Mol Cell Biochem 2006, 288:179-189.
42. Jarsch M., Brandt M., Lanzendorfer M., Haselbeck A. Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin-beta determined by surface plasmon resonance and competition binding assay. Pharmacology 2008, 81:63-69.
43. Arai A., Kanda E., Nosaka Y., Miyasaka N., Miura O. CrkL is recruited through its SH2 domain to the erythropoietin receptor and plays a role in Lyn-mediated receptor signaling. J Biol Chem 2001, 276:33282-33290.
44. Tilbrook P.A., Ingley E., Williams J.H., Hibbs M.L., Klinken S.P. Lyn tyrosine kinase is essential for erythropoietin-induced differentiation of J2E erythroid cells. EMBO J 1997, 16:1610-1619.
45. Schmidt U., van den Akker E., Parren-van Amelsvoort M., et al. Btk is required for an efficient response to erythropoietin and for SCF-controlled protection against TRAIL in erythroid progenitors. J Exp Med 2004, 199:785-795.
46. von Lindern M., Schmidt U., Beug H. Control of erythropoiesis by erythropoietin and stem cell factor: a novel role for Bruton's tyrosine kinase. Cell Cycle 2004, 3:876-879.
47. Menon M.P., Fang J., Wojchowski D.M. Core erythropoietin receptor signals for late erythroblast development. Blood 2006, 107:2662-2672.
48. Marine J.C., McKay C., Wang D., et al. SOCS3 is essential in the regulation of fetal liver erythropoiesis. Cell 1999, 98:617-627.
49. Sasaki A., Yasukawa H., Shouda T., Kitamura T., Dikic I., Yoshimura A. CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2. J Biol Chem 2000, 275:29338-29347.
50. Hortner M., Nielsch U., Mayr L.M., Heinrich P.C., Haan S. A new high affinity binding site for suppressor of cytokine signaling-3 on the erythropoietin receptor. Eur J Biochem 2002, 269:2516-2526.
51. Kile B.T., Alexander W.S. The suppressors of cytokine signalling (SOCS). Cell Mol Life Sci 2001, 58:1627-1635.
52. Meenhuis A., Verwijmeren C., Roovers O., Touw I.P. The deubiquitinating enzyme DUB2A enhances CSF3 signalling by attenuating lysosomal routing of the CSF3 receptor. Biochem J 2011, 434:343-351.